Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
复制标题
DOI：
10.1093/infdis/jiab593
复制
发表时间：
2022-04-01
期刊：
影响因子：
--
通讯作者：
Iafrate AJ
中科院分区：
文献类型：
--
作者：
Naranbhai V;Garcia-Beltran WF;Chang CC;Berrios Mairena C;Thierauf JC;Kirkpatrick G;Onozato ML;Cheng J;St Denis KJ;Lam EC;Kaseke C;Tano-Menka R;Yang D;Pavlovic M;Yang W;Kui A;Miller TE;Astudillo MG;Cahill JE;Dighe AS;Gregory DJ;Poznansky MC;Gaiha GD;Balazs AB;Iafrate AJ
了解严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗的免疫原性和有效性对于指导合理使用至关重要。我们比较了健康活动成人中 mRNA-1273、BNT-162b2 和 Ad26.COV2.S 的免疫原性。我们根据公共卫生报告对超过 4000 万人的人群水平有效性进行了逆方差荟萃分析。任一 mRNA 疫苗的单剂量产生与恢复期个体相当的抗体和中和滴度。 Ad26.COV2.S 产生较低的抗体浓度和经常检测不到的中和滴度。 mRNA1273 和 BNT162b2 中的大量和细胞毒性 T 细胞反应高于 Ad26.COV2.S 受体。无论采用何种疫苗，<50% 的接种者表现出 CD8+ T 细胞反应。在第一剂疫苗接种后，抗体浓度和中和滴度相对增加，并且在第二剂接种者中进一步增加。既往感染与高抗体浓度和中和有关，即使在单次剂量后且与疫苗无关。无论何种疫苗，对 Beta、Gamma 和 Delta 菌株的中和作用均较差。在荟萃分析中，相对于 mRNA1273，BNT162b2 对抗感染和住院的有效性较低，而 Ad26COV2.S 对抗感染、住院和死亡的有效性较低。免疫原性的变化与美国部署的 3 种疫苗的不同有效性相关。 SARS-CoV-2 疫苗的免疫原性不同（通过多种体液和 T 细胞测量）：mRNA1273 诱导的反应最强，其次是 BNT162b2； Ad26.COV2.S 诱导微弱反应。免疫原性的差异可预测人群水平针对感染、住院或死亡的有效性 (mRNA1273 > bnt162b2 > Ad26.COV2.S)。
Understanding immunogenicity and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use. We compared the immunogenicity of mRNA-1273, BNT-162b2, and Ad26.COV2.S in healthy ambulatory adults. We performed an inverse-variance meta-analysis of population-level effectiveness from public health reports in > 40 million individuals. A single dose of either mRNA vaccine yielded comparable antibody and neutralization titers to convalescent individuals. Ad26.COV2.S yielded lower antibody concentrations and frequently undetectable neutralization titers. Bulk and cytotoxic T-cell responses were higher in mRNA1273 and BNT162b2 than Ad26.COV2.S recipients. Regardless of vaccine, <50% of vaccinees demonstrated CD8+ T-cell responses. Antibody concentrations and neutralization titers increased comparably after the first dose of either vaccine, and further in recipients of a second dose. Prior infection was associated with high antibody concentrations and neutralization even after a single dose and regardless of vaccine. Neutralization of Beta, Gamma, and Delta strains were poorer regardless of vaccine. In meta-analysis, relative to mRNA1273 the effectiveness of BNT162b2 was lower against infection and hospitalization, and Ad26COV2.S was lower against infection, hospitalization, and death. Variation in the immunogenicity correlates with variable effectiveness of the 3 vaccines deployed in the United States. SARS-CoV-2 vaccines differ in immunogenicity (by multiple humoral and T-cell measures): mRNA1273 induced the strongest responses following by BNT162b2; Ad26.COV2.S induced weak responses. Differences in immunogenicity predict population-level effectiveness against infection, hospitalization, or death (mRNA1273 > bnt162b2 > Ad26.COV2.S).
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
64.5
作者：
Nathan A;Rossin EJ;Kaseke C;Park RJ;Khatri A;Koundakjian D;Urbach JM;Singh NK;Bashirova A;Tano-Menka R;Senjobe F;Waring MT;Piechocka-Trocha A;Garcia-Beltran WF;Iafrate AJ;Naranbhai V;Carrington M;Walker BD;Gaiha GD
通讯作者：
Gaiha GD
影响因子：
120.7
作者：
Stephenson, Kathryn E.;Le Gars, Mathieu;Barouch, Dan H.
通讯作者：
Barouch, Dan H.
DOI：
10.1001/jama.2021.88282021
发表时间：
2021-06-03
影响因子：
120.7
作者：
Cohen, Myron S.;Nirula, Ajay;Skovronsky, Daniel M.
通讯作者：
Skovronsky, Daniel M.
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group